Annual Report on Asian Regional Consortium for Headache (ARCH) in 2020

8th ARCH Conference
Originally the 8th Asian Regional Conference of Headache (ARCH) will be held jointly with the 17th Asian Oceanian Congress of Neurology (AOCN) on October 8-11, 2020 in Taipei, Taiwan. However, because of the COVID-19 pandemic, the date of the ARCH meeting was re-scheduled to Apr. 3rd, 2021. Considering that the COVID-19 might still affect most of the world in April 2021, the 8th ARCH will be a hybrid conference combing live face-to-face events and virtual online components. See the Appendix for the tentative schedule.

Hi-ARCH
The first Hi-ACRH meeting, an educational programme for early career neurologists and research scientists interested in headache medicine in the Asian-Oceania Region, will be cancelled and rescheduled for practicality.

Shuu-Jiun Wang
Chair
Appendix:

ARCH meeting: Therapeutic armamentarium in headache disorders

Place: Taipei International Convention Center, Taipei, TAIWAN

Time: 2021/4/3 (Sat)

Session 0830-1000 (Moderator: Shuu-Jiun Wang, David Dodick)
0830-0900 Messoud Ashina (Denmark): Experimental human studies in headache disorders
0900-0920 Wei-Ta Chen (Taiwan): Are tension-type headache and migraine two points on a continuum?
0920-0940 Tissa Wijeratne (Australia): Cluster headache: established and emerging treatments
0940-1000 Shih-Pin Chen (Taiwan): Demystifying Reversible Cerebral Vasospasm Syndrome

Session 1030-1200 (Moderator: Kao-Chang Lin, Messoud Ashina)
1030-1100 David Dodick (US): Anti-CGRP monoclonal antibodies as new therapies for migraine
1100-1120 Chiieong David Lau (Taiwan): Treating migraine with neuromodulation: the role of abnormal neurophysiology and maladaptive plasticity
1120-1140 Siwaporn Chankrachang (Thailand): Headache management: the ASEAN way
1140-1200 Miji Lee (Korea): Treatment of medication-overuse headache: predictors and challenges

Lunch symposium 1200-1330 (Moderator: TBD)
1210-1240 Cristina Tassorelli (Italy): Headache treatment guidelines: the role of anti-CGRP monoclonal antibodies
1240-1300 Fumihiko Sakai (Japan): Anti-CGRP monoclonal antibodies for migraine: Asian experience

Session 1330-1500 (Moderator: Wei-Ta Chen, Artemio A. Roxas Jr)
1330-1350 Chin-Sang Chung (Korea): Impact of comorbidity on the treatment and prognosis of headache disorders
1350-1410 Jonathan Ong (Singapore): Individualized treatment for migraine
1410-1430 Yang Chun-Pai (Taiwan): Acupuncture benefits migraine: myth or science?
1430-1500 Allan Purdy (US): The future of headache treatment